217 related articles for article (PubMed ID: 25105841)
1. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.
Nikolaev SI; Garieri M; Santoni F; Falconnet E; Ribaux P; Guipponi M; Murray A; Groet J; Giarin E; Basso G; Nizetic D; Antonarakis SE
Nat Commun; 2014 Aug; 5():4654. PubMed ID: 25105841
[TBL] [Abstract][Full Text] [Related]
2. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
3. RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia.
Koschut D; Ray D; Li Z; Giarin E; Groet J; Alić I; Kham SK; Chng WJ; Ariffin H; Weinstock DM; Yeoh AE; Basso G; Nižetić D
Oncogene; 2021 Jan; 40(4):746-762. PubMed ID: 33247204
[TBL] [Abstract][Full Text] [Related]
4. Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.
Hanada I; Terui K; Ikeda F; Toki T; Kanezaki R; Sato T; Kamio T; Kudo K; Sasaki S; Takahashi Y; Hayashi Y; Inukai T; Kojima S; Koike K; Kosaka Y; Kobayashi M; Imaizumi M; Mitsui T; Hori H; Hara J; Horibe K; Nagai J; Goto H; Ito E
Genes Chromosomes Cancer; 2014 Nov; 53(11):902-10. PubMed ID: 25044358
[TBL] [Abstract][Full Text] [Related]
5. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
7. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
Buitenkamp TD; Pieters R; Gallimore NE; van der Veer A; Meijerink JP; Beverloo HB; Zimmermann M; de Haas V; Richards SM; Vora AJ; Mitchell CD; Russell LJ; Schwab C; Harrison CJ; Moorman AV; van den Heuvel-Eibrink MM; den Boer ML; Zwaan CM
Leukemia; 2012 Oct; 26(10):2204-11. PubMed ID: 22441210
[TBL] [Abstract][Full Text] [Related]
8. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
Kearney L; Gonzalez De Castro D; Yeung J; Procter J; Horsley SW; Eguchi-Ishimae M; Bateman CM; Anderson K; Chaplin T; Young BD; Harrison CJ; Kempski H; So CW; Ford AM; Greaves M
Blood; 2009 Jan; 113(3):646-8. PubMed ID: 18927438
[TBL] [Abstract][Full Text] [Related]
9. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
[TBL] [Abstract][Full Text] [Related]
10. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
Mullighan CG; Collins-Underwood JR; Phillips LA; Loudin MG; Liu W; Zhang J; Ma J; Coustan-Smith E; Harvey RC; Willman CL; Mikhail FM; Meyer J; Carroll AJ; Williams RT; Cheng J; Heerema NA; Basso G; Pession A; Pui CH; Raimondi SC; Hunger SP; Downing JR; Carroll WL; Rabin KR
Nat Genet; 2009 Nov; 41(11):1243-6. PubMed ID: 19838194
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.
Gaikwad A; Rye CL; Devidas M; Heerema NA; Carroll AJ; Izraeli S; Plon SE; Basso G; Pession A; Rabin KR
Br J Haematol; 2009 Mar; 144(6):930-2. PubMed ID: 19120350
[TBL] [Abstract][Full Text] [Related]
12. Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients.
Page EC; Heatley SL; Yeung DT; Thomas PQ; White DL
Cancer Lett; 2018 Sep; 432():69-74. PubMed ID: 29879498
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Schmäh J; Fedders B; Panzer-Grümayer R; Fischer S; Zimmermann M; Dagdan E; Bens S; Schewe D; Moericke A; Alten J; Bleckmann K; Siebert R; Schrappe M; Stanulla M; Cario G
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28371317
[TBL] [Abstract][Full Text] [Related]
14. CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
Roll JD; Reuther GW
Cancer Res; 2010 Oct; 70(19):7347-52. PubMed ID: 20807819
[TBL] [Abstract][Full Text] [Related]
15. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Harvey RC; Mullighan CG; Chen IM; Wharton W; Mikhail FM; Carroll AJ; Kang H; Liu W; Dobbin KK; Smith MA; Carroll WL; Devidas M; Bowman WP; Camitta BM; Reaman GH; Hunger SP; Downing JR; Willman CL
Blood; 2010 Jul; 115(26):5312-21. PubMed ID: 20139093
[TBL] [Abstract][Full Text] [Related]
16. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
17. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
[TBL] [Abstract][Full Text] [Related]
18. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
[TBL] [Abstract][Full Text] [Related]
19. Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.
Potter N; Jones L; Blair H; Strehl S; Harrison CJ; Greaves M; Kearney L; Russell LJ
Leukemia; 2019 Apr; 33(4):893-904. PubMed ID: 30487598
[TBL] [Abstract][Full Text] [Related]
20. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
